Johnson & Johnson has expanded its consumer health product offering in the UK by securing the Rx-to-OTC switch of its Sudafed Plus Blocked Nose nasal spray.
The Medicines and Healthcare products Regulatory Agency approved an application from J&J’s McNeil Products Limited subsidiary to reclassify Sudafed Plus – which contains xylometazoline hydrochloride 1mg/ml (0
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?